Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 7/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.36 |
| ▸ | ALB | P02768 | 2/20 | 0.36 |
| ▸ | VCP | P55072 | 1/20 | 0.36 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.35 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499026 | 0.90 | ITGB3 (0.37) | ITGAVITGB3ITGA2BNR3C1ALB | |
| SCHEMBL6499964 | 0.88 | KAT6A (0.43) | ITGAVITGB3ITGA2BP2RY12CNR1 | |
| SCHEMBL6498525 | 0.86 | ITGB3 (0.53) | ITGAVITGB3ITGA2BITGB1 | |
| SCHEMBL6507021 | 0.86 | ITGB3 (0.41) | ITGAVITGB3ITGA2BCNR1CNR2 | |
| SCHEMBL6498611 | 0.85 | DRD2 (0.41) | ITGAVITGB3ITGA2BDRD2DRD3 | |
| SCHEMBL6500799 | 0.85 | ITGAV (0.51) | ITGAVITGB3ITGA2B | |
| SCHEMBL6500015 | 0.84 | DRD2 (0.40) | ITGAVITGB3ITGA2BP2RY12VCP | |
| SCHEMBL6499024 | 0.80 | ITGAV (0.40) | ITGAVITGB3ITGA2BNR3C1ITGB1 | |
| SCHEMBL7464438 | 0.79 | DRD2 (0.42) | ITGAVITGB3ITGA2BP2RY12VCP | |
| SCHEMBL27551456 | 0.79 | ITGB3 (0.51) | ITGAVITGB3ITGA2BITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | claimed |
| EP-1229024-A1 | m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM | MEIJI SEIKA KAISHA LTD. (JP) | 2002-08-07 | — | — | EP | claimed |
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | AJITO KEIICHI (JP) | 2005-03-17 | — | — | US | disclosed |
| EP-1229024-A1 | m-SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING INTEGRIN ALPHA-V BETA-3 ANTAGONISM | MEIJI SEIKA KAISHA LTD. (JP) | 2002-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059669-A1 | M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity | ITGAV, ITGB3, ITGA4 | ITGAV 1/4885ITGB3 2/4885ITGA2B 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.